Get notified of page updates

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

High-risk localized prostate cancer

Clinicaltrials.gov identifier:
NCT04030559
PRINTER FRIENDLY PAGE
Overview
Who Can Join
Glossary on
off

About the Study

NOTE: This study is no longer recruiting people. 

This study will look at how well the niraparib works, when given before a radical prostatectomy, for people with high-risk cancer that has not spread to other parts of the body, and who have a tumor mutation in any of the following genes:BRCA1/2, , CDK12, CHEK1/2 FANCA, FANCD2, FANCL, GEN1, , , RAD51, , and .

This Study is Open To:

NOTE: This study is no longer recruiting people.

This Study is NOT Open To:

NOTE: This study is no longer recruiting people.

High-risk localized prostate cancer

Clinicaltrials.gov identifier:
NCT04030559
PRINTER FRIENDLY PAGE